D-Proton.pptx
•Download as PPTX, PDF•
0 likes•205 views
This document provides information about Gastroesophageal reflux disease (GERD), esophagitis, peptic ulcers, and current proton pump inhibitor (PPI) treatment options. It then introduces D-Proton, a new PPI containing dexlansoprazole, indicating it can overcome drawbacks of conventional PPIs. Details are provided on the drug's mechanism of action, dosing for GERD and erosive esophagitis, target doctors, the PPI market landscape, and marketing guidelines to achieve sales targets for D-Proton.
Report
Share
Report
Share
Recommended
Dexilant (Dexlansoprazole)
This document summarizes information about Dexlansoprazole (DEXILANT), a proton pump inhibitor used to treat gastroesophageal reflux disease (GERD). It notes that GERD is common worldwide, with prevalence rates ranging from 5-48% depending on the country. DEXILANT contains two types of pellets that release at different pH levels to provide dual delayed release of the drug. It is indicated for healing erosive esophagitis, maintaining healing of EE, and treating heartburn from symptomatic non-erosive GERD. The document reviews dosage forms, advantages like flexibility with timing, potential off-label uses, and common side effects like gas and nausea.
Advance Gerd Voniza Presenatation.pptx
This document provides information on Gastroesophageal Reflux Disease (GERD). It begins with definitions and descriptions of GERD and its typical and atypical symptoms. It then discusses the pathophysiology, impact on quality of life, classification (NERD, erosive esophagitis, Barrett's esophagus), and symptoms. Diagnostic testing options are presented including endoscopy, biopsies, and pH monitoring. Risk factors, prevalence worldwide, and limitations of current PPI therapies are reviewed. Finally, the document introduces Vonoprazan as a novel potassium-competitive acid blocker with advantages over PPIs such as longer half-life, rapid and sustained acid control demonstrated in clinical trials, and superior
P cab
Potassium-competitive acid blockers (P-CABs) are a new class of drugs that inhibit gastric acid secretion by competitively binding to the potassium site of the H+/K+ ATPase pump. The first P-CAB, vonoprazan, was introduced in Japan in 2015 and has been shown to have more rapid and consistent acid suppression than proton pump inhibitors (PPIs). P-CABs may overcome some limitations of PPIs like slow onset of action, variability due to CYP2C19 metabolism, and acid rebound effects. Vonoprazan in particular has demonstrated efficacy in treating acid-related diseases like gastroesophageal reflux disease and peptic ulcers, as
Esomeprazole marketing plan by mehedee
This document discusses marketing strategies for the proton pump inhibitor brand Esotid in Bangladesh. It notes that Esotid contains the molecule Esomeprazole, which has greater bioavailability than other PPIs and can maintain intragastric pH above 4 for over 17 hours. The document encourages promoting Esotid for gastroesophageal reflux disease (GERD) and gastroesophageal reflux-induced chronic cough (GERC), highlighting clinical trial results showing Esomeprazole's superiority to Omeprazole for recovering GERC patients. Promotional materials and messaging are provided to establish Esotid injection in hospitals and inform doctors of Esotid's benefits over other PPI brands for NSAID-
Esomeprazole plan
This document provides an overview and marketing plan for the launch of the new PPI drug Esomeprazole. The summary is:
1) Esomeprazole is aiming to target the large and growing PPI drug market by positioning itself as the most advanced PPI with higher bioavailability and safety.
2) The marketing plan includes pre-launch market research, targeting physicians and pharmacists with differentiated positioning messages emphasizing Esomeprazole as the "first choice" PPI.
3) Tactics will include sequential physician visits, message-related promotions, and a focus on tenders, competitions management, and direct-to-customer and consumer campaigns. The goal is to achieve the
Marketing Plan of Esomeprazole
- The document provides sales forecasts for Esoz 20, an esomeprazole magnesium tablet, for the first year in quarterly projections. It estimates sales of Rs. 2.5 crore for the year with sales increasing each month and quarter as penetration increases.
- A promotional budget of Rs. 30 lakh is allocated equally across the 4 quarters to market the brand to gastroenterologists, general physicians, surgeons and gynaecologists in metro and class 1/2 cities.
- Key activities include product sampling, branding materials, and print advertisements. Pricing is set at Rs. 15.93 per tablet with a company margin of 60% after trade discounts.
VONAPRAZAN presentation.pptx
This document discusses gastrointestinal reflux disease (GERD) and approaches to treating it. It begins by defining GERD and describing its typical clinical presentations. It notes that lifestyle factors like obesity have only weak evidence of aggravating GERD symptoms. Certain medications are also described as potentially aggravating GERD. The document then discusses the phenotypic classification of GERD and reviews the symptoms. It provides data on the prevalence of GERD worldwide and in particular countries and regions. Reasons for treatment failure with proton pump inhibitors are summarized. New therapies for GERD like vonoprazan, a potassium-competitive acid blocker, are introduced and its advantages over proton pump inhibitors are highlighted. Clinical evidence is presented demonstrating
Esomeprazole medical knowledge
Esomeprazole is the most advanced PPI for acid regulation. It is more effective than omeprazole at reducing acid production due to higher bioavailability from less first-pass metabolism. Esomeprazole has indications for treating GERD, dyspepsia, H. pylori infection, erosive esophagitis, NSAID-induced ulcers, and pathological hypersecretory conditions. It has typical PPI side effects like diarrhea and headaches. Esomeprazole has drug-drug interactions and its dosage depends on the condition being treated, ranging from once daily for GERD to twice daily for Zollinger-Ellison syndrome.
Recommended
Dexilant (Dexlansoprazole)
This document summarizes information about Dexlansoprazole (DEXILANT), a proton pump inhibitor used to treat gastroesophageal reflux disease (GERD). It notes that GERD is common worldwide, with prevalence rates ranging from 5-48% depending on the country. DEXILANT contains two types of pellets that release at different pH levels to provide dual delayed release of the drug. It is indicated for healing erosive esophagitis, maintaining healing of EE, and treating heartburn from symptomatic non-erosive GERD. The document reviews dosage forms, advantages like flexibility with timing, potential off-label uses, and common side effects like gas and nausea.
Advance Gerd Voniza Presenatation.pptx
This document provides information on Gastroesophageal Reflux Disease (GERD). It begins with definitions and descriptions of GERD and its typical and atypical symptoms. It then discusses the pathophysiology, impact on quality of life, classification (NERD, erosive esophagitis, Barrett's esophagus), and symptoms. Diagnostic testing options are presented including endoscopy, biopsies, and pH monitoring. Risk factors, prevalence worldwide, and limitations of current PPI therapies are reviewed. Finally, the document introduces Vonoprazan as a novel potassium-competitive acid blocker with advantages over PPIs such as longer half-life, rapid and sustained acid control demonstrated in clinical trials, and superior
P cab
Potassium-competitive acid blockers (P-CABs) are a new class of drugs that inhibit gastric acid secretion by competitively binding to the potassium site of the H+/K+ ATPase pump. The first P-CAB, vonoprazan, was introduced in Japan in 2015 and has been shown to have more rapid and consistent acid suppression than proton pump inhibitors (PPIs). P-CABs may overcome some limitations of PPIs like slow onset of action, variability due to CYP2C19 metabolism, and acid rebound effects. Vonoprazan in particular has demonstrated efficacy in treating acid-related diseases like gastroesophageal reflux disease and peptic ulcers, as
Esomeprazole marketing plan by mehedee
This document discusses marketing strategies for the proton pump inhibitor brand Esotid in Bangladesh. It notes that Esotid contains the molecule Esomeprazole, which has greater bioavailability than other PPIs and can maintain intragastric pH above 4 for over 17 hours. The document encourages promoting Esotid for gastroesophageal reflux disease (GERD) and gastroesophageal reflux-induced chronic cough (GERC), highlighting clinical trial results showing Esomeprazole's superiority to Omeprazole for recovering GERC patients. Promotional materials and messaging are provided to establish Esotid injection in hospitals and inform doctors of Esotid's benefits over other PPI brands for NSAID-
Esomeprazole plan
This document provides an overview and marketing plan for the launch of the new PPI drug Esomeprazole. The summary is:
1) Esomeprazole is aiming to target the large and growing PPI drug market by positioning itself as the most advanced PPI with higher bioavailability and safety.
2) The marketing plan includes pre-launch market research, targeting physicians and pharmacists with differentiated positioning messages emphasizing Esomeprazole as the "first choice" PPI.
3) Tactics will include sequential physician visits, message-related promotions, and a focus on tenders, competitions management, and direct-to-customer and consumer campaigns. The goal is to achieve the
Marketing Plan of Esomeprazole
- The document provides sales forecasts for Esoz 20, an esomeprazole magnesium tablet, for the first year in quarterly projections. It estimates sales of Rs. 2.5 crore for the year with sales increasing each month and quarter as penetration increases.
- A promotional budget of Rs. 30 lakh is allocated equally across the 4 quarters to market the brand to gastroenterologists, general physicians, surgeons and gynaecologists in metro and class 1/2 cities.
- Key activities include product sampling, branding materials, and print advertisements. Pricing is set at Rs. 15.93 per tablet with a company margin of 60% after trade discounts.
VONAPRAZAN presentation.pptx
This document discusses gastrointestinal reflux disease (GERD) and approaches to treating it. It begins by defining GERD and describing its typical clinical presentations. It notes that lifestyle factors like obesity have only weak evidence of aggravating GERD symptoms. Certain medications are also described as potentially aggravating GERD. The document then discusses the phenotypic classification of GERD and reviews the symptoms. It provides data on the prevalence of GERD worldwide and in particular countries and regions. Reasons for treatment failure with proton pump inhibitors are summarized. New therapies for GERD like vonoprazan, a potassium-competitive acid blocker, are introduced and its advantages over proton pump inhibitors are highlighted. Clinical evidence is presented demonstrating
Esomeprazole medical knowledge
Esomeprazole is the most advanced PPI for acid regulation. It is more effective than omeprazole at reducing acid production due to higher bioavailability from less first-pass metabolism. Esomeprazole has indications for treating GERD, dyspepsia, H. pylori infection, erosive esophagitis, NSAID-induced ulcers, and pathological hypersecretory conditions. It has typical PPI side effects like diarrhea and headaches. Esomeprazole has drug-drug interactions and its dosage depends on the condition being treated, ranging from once daily for GERD to twice daily for Zollinger-Ellison syndrome.
10 step marketing plan for aforvir
This document outlines a 10 step marketing plan for Aforvir, an affordable antihistamine medication for children. The target market is physicians who treat allergies in children aged 6 months to 5 years. Aforvir will position itself as effective, affordable, and pleasant tasting compared to competitors. Key elements of the marketing plan include an emotional promotional campaign centered on reuniting children with pets, competitive pricing, and regular physician representative visits to promote Aforvir. The overall antihistamine market is valued at $116 million growing at 16% annually, and the goal is for Aforvir to gain a larger share through this marketing strategy.
Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...
Last Updated: 15th MAY: ALL NEW STUDIES INCLUDED. After more than 2 decades of USE, ABUSE, OVERUSE.... PPIs are under scanner. Not just Osteoporosis, other complications but Proton pump inhibitors have been confirmed to cause insistent Kidney failure/disease, heart attacks to name a few. This new revelations should open the eyes of so many consumers and several doctors.
Brand Plan for the launch of Brand-X
This document provides a brand plan for launching Brand-X (Clopidogrel 75mg) in the Bangalore market. It includes a market analysis of the anti-platelet drug market in India, a SWOT analysis of Brand-X, and secondary sales planning for 2015-2017 with targets to increase sales each year. The document also outlines pre-launch and post-launch strategies for engaging doctors and pharmacies in Bangalore. It proposes tracking sales performance and providing field motivation programs to incentivize sales representatives.
glyxambi
This document discusses the clinical profile and efficacy of the combination drug GLYXAMBI, which contains empagliflozin and linagliptin. It summarizes clinical trial results showing that GLYXAMBI provides significant reductions in HbA1c and body weight compared to the individual components alone in patients with type 2 diabetes. Guidelines from major diabetes organizations have been updated to recommend SGLT2 inhibitors like empagliflozin and GLP-1 receptor agonists to reduce cardiovascular risk based on positive cardiovascular outcomes trial results.
Stomach
Vonoprazan is a novel potassium-competitive acid blocker (PCAB) that provides more potent and sustained acid suppression compared to proton pump inhibitors (PPIs). Studies show Vonoprazan achieves faster and higher gastric pH control from the first dose. It is also effective for Helicobacter pylori eradication, achieving higher eradication rates than PPI-based triple therapies. Vonoprazan has also shown non-inferiority to lansoprazole for healing erosive esophagitis with higher cure rates.
Nimalox re-branding marketing plan
Nimalox is a non steroidal anti inflammatory drug with
analgesic and antipyretic properties and cox-2
selective inhibition
it's a study to re-branding Nimalox
MBA Cairo University
Proton pump inhibitors present and future a review
This document provides an overview of proton pump inhibitors (PPIs), including a brief history of their development and their use in treating acid-related disorders. It discusses the physiology of acid secretion in the stomach and the discovery of the proton pump. It also summarizes several acid-related disorders like ulcers, GERD, and Zollinger-Ellison syndrome that are treated by inhibiting acid secretion. The document reviews the clinical significance and advantages of PPIs compared to previous drugs while also mentioning some limitations and efforts to develop new treatments.
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada SelimBangabandhu Sheikh Mujib Medical University
Empagliflozin is an SGLT2 inhibitor that has shown cardiovascular benefits in clinical trials. SGLT2 inhibitors work by inhibiting glucose reabsorption in the kidneys, leading to increased glucose excretion and reduced blood glucose levels. Empagliflozin in particular has demonstrated reductions in cardiovascular death and hospitalization for heart failure. However, SGLT2 inhibitors also carry risks like genitourinary infections and volume depletion that require monitoring. Overall, SGLT2 inhibitors provide an additional treatment option for type 2 diabetes that can help lower glucose levels while also reducing cardiovascular outcomes.Esomeprazole product presentation
Esomeprazole Product Presentation for MPO's.
The primary uses of esomeprazole are gastroesophageal reflux disease, treatment and maintenance of erosive esophagitis, treatment of duodenal ulcers caused by H. pylori, prevention of gastric ulcers in those on chronic NSAID therapy, and treatment of gastrointestinal ulcers associated with Crohn's disease.
Rabeprazole sodium and domperidone capsules.pdf.pdf
Here, we will discuss rabeprazole sodium and domperidone capsule’s uses, dosage, mechanism, side effects, warnings or precautions.
Rabeprazole is an anti-ulcer drug, whereas domperidone comes in the anti-emetic (or prokinetic) category. This combination of rabeprazole and domperidone medicines reliefs in stomach related problems like acidity, ulcer & gas.
Rabeprazole belongs to the proton pump inhibitors (PPIs) class. This medicine suppresses the excess acid in your stomach by inhibiting the proton pump.
Rabeprazole is a newer proton pump inhibitor drug that strongly stops gastric acid secretion. This medicine is a potent and fastest acid suppression than other PPIs. It starts to work within 5 minutes.
The combination of rabeprazole and domperidone is commonly used for treating ulcers and gastroesophageal reflux disease (GERD).
Rabeprazole is usually preferred for an empty stomach. Because it is more effective if you take an empty stomach once daily in the morning.
When you take a Rabeprazole sodium tablet or capsule on an empty stomach, it goes into your bloodstream. And it gets converted into the active form of sulphenamide (sulfenamide).
This active form inhibits the proton pump H+K+ ATPase enzyme. In this way, it helps in acid suppression.
The use of rabeprazole sodium is not recommended in pregnancy and breastfeeding. It should be used if clearly needed. On the other hand, domperidone has shown teratogenicity in pregnant animals. So, the use of domperidone should be avoided during pregnancy.
Although, all proton pump inhibitor (PPI) drugs have almost similar efficacy and safety profile. But clinically, rabeprazole has shown better results than other PPIs.
Rabeprazole sodium is a well-tolerated, effective and safe proton pump inhibitor.
Based on clinical experience and few clinical trials, rabeprazole is considered stronger and more powerful than other PPIs.
In addition to providing satisfying relief of symptoms of GERD, rabeprazole sodium and domperidone capsules are also well tolerated.
The use of rabeprazole sodium and domperidones capsules are not recommended in children, the elderly, liver disease, heart disease, pregnancy, and breastfeeding.
Since it is a prescription-based medicine, so you don’t take self-medication. You must consult your doctor before taking a rabeprazole sodium and domperidone capsules.
Losart (Losar
This document outlines the business plan for Losartan Potassium (LOSART) for 2015. It summarizes that hypertension prevalence in Bangladesh is approximately 20% according to different sources. The cardiovascular drug market is valued at 988 crores with antihypertensives comprising 636 crores. LOSART has a 29.24% share of the antihypertensive market as the second most prescribed generic. The plan identifies opportunities to increase market share by focusing on specialty physicians and improving performance in metro areas. Objectives for 2015 include achieving 10% growth, a 4.9% market share, and reaching the number 3 market position.
Dapagliflozin- a novel SGLT2 inhibitor
1) Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that works by inhibiting glucose reabsorption in the kidney and increasing glucose excretion in the urine.
2) Studies have shown that dapagliflozin reduces HbA1c and body weight when used as monotherapy or as add-on therapy to other glucose-lowering medications, including metformin, sulfonylureas, pioglitazone, and insulin. Reductions in HbA1c were sustained over 102 weeks.
3) Common side effects of dapagliflozin include increased urinary tract and genital infections, as well
Me rck’s new product development & launch strategy for
Merck was developing a new strategy to market its diabetes drug Januvia. The strategy involved using fewer sales representatives and increasing digital and online advertising. Merck found its sales force was more productive using these new methods, such as video detailing in doctors' offices. Merck also emphasized better targeting of physicians and increasing disease education for patients through tools like diabetes maps. The product manager for Januvia faced a dilemma in deciding whether to position the drug earlier or later in the progression of diabetes. Januvia saw strong initial launch with 14% of new Type 2 diabetes prescriptions. Merck competed against other diabetes drugs and was considering expanding into alternative treatment areas like insulin delivery devices, which showed a growing global market.
Prucalopride
This document discusses chronic constipation and provides information about Prulitop, a new treatment option. It summarizes that chronic constipation is a common issue, with various causes and symptoms. Current treatment options include laxatives, but these have risks if abused. Prulitop contains prucalopride, which works by agonizing 5HT4 receptors in the gut to increase fluid secretion and speed up transit time, providing an alternative to removed treatments. The document outlines the market for constipation drugs, target doctors and indications, and dosage recommendations for Prulitop.
Potassium competitive acid blocker.pptx
Pcab is new class of drug recently marketed in bangladesh.Study shows superior efficacy in comparison to conventional PPI
EXALIN Launching Presentation
The document provides market data on antihistamine drugs in Bangladesh for the first quarter of 2015. It details the total market size of 293.60 crore and lists the top selling generic drugs by value, led by cetirizine at 68.79 crore. The market share of each generic is also shown, with cetirizine and fexofenadine each holding 23% and 22% respectively. Growth rates for the market are provided, with rupatadine seeing the highest growth of 67.93%. Brand performance data for rupatadine brands in Bangladesh is outlined. Finally, the document introduces Exalin, a new 10mg rupatadine tablet from Opso Saline
Diclofenac Injection BRAND PLAN
Diclofenac Injection BRAND PLAN, Marketing activity, Pharma Brand Plan, Pharma Marketing.branding promotion, diclofenac injection brand plan, launch plan, marketing activity, pharma brand plan, pharma marketing
Oliset Olmesartan
Olmesartan medoxomil is an angiotensin II receptor antagonist which is used for the treatment of high blood pressure. An ester prodrug, it is completely and rapidly hydrolyzed to the active acid form. It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents
Neoslim™ Final
The marketing plan proposes promoting Neoslim, a new subcutaneously administered combination anti-obesity drug, to establish it as the leading anti-obesity drug brand. The objectives are to minimize patient dropout rates, increase US market penetration and later expand to Europe. The plan details promotional tactics targeting physicians, consumers, and payers to communicate Neoslim's positioning as superior to other anti-obesity drugs. Key assumptions include Neoslim gaining greater acceptance over competitors through lower dropout rates and higher market penetration, potentially capturing the statin and Meridia markets in the US.
Vildagliptin in the management of Type 2 Diabetes mellitus
This document provides an overview of a continuing medical education (CME) program on the use of vildagliptin in managing type 2 diabetes mellitus (T2DM). The presentation covers the global burden of diabetes, pathophysiology of T2DM, limitations of current oral therapies, the incretin system, and the mechanisms and effects of DPP-4 inhibitors like vildagliptin. It discusses how vildagliptin improves pancreatic beta cell function and glucose control by prolonging the actions of incretins GLP-1 and GIP. The presentation also highlights the differences between incretin mimetics and DPP-4 inhibitors.
Esophagitis
Esophagitis is inflammation of the esophagus that can have various causes like acid reflux, infections, medications, radiation, and more. Common symptoms include dysphagia, heartburn, and painful swallowing. Diagnosis involves endoscopy and biopsy. Treatment depends on the underlying cause but may include lifestyle changes, antacids, H2 blockers, proton pump inhibitors, and surgery in some cases. Complications can include strictures and Barrett's esophagus.
PEPTIC ULCER
Peptic ulcer disease refers to ulcers in the stomach or duodenum caused by an imbalance of digestive fluids. Common causes include infection with H. pylori bacteria and use of NSAIDs like aspirin. Symptoms may include abdominal pain, nausea, vomiting, or blood in stool. Treatment involves eradicating H. pylori with antibiotic combinations, managing NSAID use, and prescribing proton pump inhibitors to reduce acid production and promote healing. Proton pump inhibitors are also used to treat gastroesophageal reflux disease, which occurs when stomach acid backs up into the esophagus.
More Related Content
What's hot
10 step marketing plan for aforvir
This document outlines a 10 step marketing plan for Aforvir, an affordable antihistamine medication for children. The target market is physicians who treat allergies in children aged 6 months to 5 years. Aforvir will position itself as effective, affordable, and pleasant tasting compared to competitors. Key elements of the marketing plan include an emotional promotional campaign centered on reuniting children with pets, competitive pricing, and regular physician representative visits to promote Aforvir. The overall antihistamine market is valued at $116 million growing at 16% annually, and the goal is for Aforvir to gain a larger share through this marketing strategy.
Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...
Last Updated: 15th MAY: ALL NEW STUDIES INCLUDED. After more than 2 decades of USE, ABUSE, OVERUSE.... PPIs are under scanner. Not just Osteoporosis, other complications but Proton pump inhibitors have been confirmed to cause insistent Kidney failure/disease, heart attacks to name a few. This new revelations should open the eyes of so many consumers and several doctors.
Brand Plan for the launch of Brand-X
This document provides a brand plan for launching Brand-X (Clopidogrel 75mg) in the Bangalore market. It includes a market analysis of the anti-platelet drug market in India, a SWOT analysis of Brand-X, and secondary sales planning for 2015-2017 with targets to increase sales each year. The document also outlines pre-launch and post-launch strategies for engaging doctors and pharmacies in Bangalore. It proposes tracking sales performance and providing field motivation programs to incentivize sales representatives.
glyxambi
This document discusses the clinical profile and efficacy of the combination drug GLYXAMBI, which contains empagliflozin and linagliptin. It summarizes clinical trial results showing that GLYXAMBI provides significant reductions in HbA1c and body weight compared to the individual components alone in patients with type 2 diabetes. Guidelines from major diabetes organizations have been updated to recommend SGLT2 inhibitors like empagliflozin and GLP-1 receptor agonists to reduce cardiovascular risk based on positive cardiovascular outcomes trial results.
Stomach
Vonoprazan is a novel potassium-competitive acid blocker (PCAB) that provides more potent and sustained acid suppression compared to proton pump inhibitors (PPIs). Studies show Vonoprazan achieves faster and higher gastric pH control from the first dose. It is also effective for Helicobacter pylori eradication, achieving higher eradication rates than PPI-based triple therapies. Vonoprazan has also shown non-inferiority to lansoprazole for healing erosive esophagitis with higher cure rates.
Nimalox re-branding marketing plan
Nimalox is a non steroidal anti inflammatory drug with
analgesic and antipyretic properties and cox-2
selective inhibition
it's a study to re-branding Nimalox
MBA Cairo University
Proton pump inhibitors present and future a review
This document provides an overview of proton pump inhibitors (PPIs), including a brief history of their development and their use in treating acid-related disorders. It discusses the physiology of acid secretion in the stomach and the discovery of the proton pump. It also summarizes several acid-related disorders like ulcers, GERD, and Zollinger-Ellison syndrome that are treated by inhibiting acid secretion. The document reviews the clinical significance and advantages of PPIs compared to previous drugs while also mentioning some limitations and efforts to develop new treatments.
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada SelimBangabandhu Sheikh Mujib Medical University
Empagliflozin is an SGLT2 inhibitor that has shown cardiovascular benefits in clinical trials. SGLT2 inhibitors work by inhibiting glucose reabsorption in the kidneys, leading to increased glucose excretion and reduced blood glucose levels. Empagliflozin in particular has demonstrated reductions in cardiovascular death and hospitalization for heart failure. However, SGLT2 inhibitors also carry risks like genitourinary infections and volume depletion that require monitoring. Overall, SGLT2 inhibitors provide an additional treatment option for type 2 diabetes that can help lower glucose levels while also reducing cardiovascular outcomes.Esomeprazole product presentation
Esomeprazole Product Presentation for MPO's.
The primary uses of esomeprazole are gastroesophageal reflux disease, treatment and maintenance of erosive esophagitis, treatment of duodenal ulcers caused by H. pylori, prevention of gastric ulcers in those on chronic NSAID therapy, and treatment of gastrointestinal ulcers associated with Crohn's disease.
Rabeprazole sodium and domperidone capsules.pdf.pdf
Here, we will discuss rabeprazole sodium and domperidone capsule’s uses, dosage, mechanism, side effects, warnings or precautions.
Rabeprazole is an anti-ulcer drug, whereas domperidone comes in the anti-emetic (or prokinetic) category. This combination of rabeprazole and domperidone medicines reliefs in stomach related problems like acidity, ulcer & gas.
Rabeprazole belongs to the proton pump inhibitors (PPIs) class. This medicine suppresses the excess acid in your stomach by inhibiting the proton pump.
Rabeprazole is a newer proton pump inhibitor drug that strongly stops gastric acid secretion. This medicine is a potent and fastest acid suppression than other PPIs. It starts to work within 5 minutes.
The combination of rabeprazole and domperidone is commonly used for treating ulcers and gastroesophageal reflux disease (GERD).
Rabeprazole is usually preferred for an empty stomach. Because it is more effective if you take an empty stomach once daily in the morning.
When you take a Rabeprazole sodium tablet or capsule on an empty stomach, it goes into your bloodstream. And it gets converted into the active form of sulphenamide (sulfenamide).
This active form inhibits the proton pump H+K+ ATPase enzyme. In this way, it helps in acid suppression.
The use of rabeprazole sodium is not recommended in pregnancy and breastfeeding. It should be used if clearly needed. On the other hand, domperidone has shown teratogenicity in pregnant animals. So, the use of domperidone should be avoided during pregnancy.
Although, all proton pump inhibitor (PPI) drugs have almost similar efficacy and safety profile. But clinically, rabeprazole has shown better results than other PPIs.
Rabeprazole sodium is a well-tolerated, effective and safe proton pump inhibitor.
Based on clinical experience and few clinical trials, rabeprazole is considered stronger and more powerful than other PPIs.
In addition to providing satisfying relief of symptoms of GERD, rabeprazole sodium and domperidone capsules are also well tolerated.
The use of rabeprazole sodium and domperidones capsules are not recommended in children, the elderly, liver disease, heart disease, pregnancy, and breastfeeding.
Since it is a prescription-based medicine, so you don’t take self-medication. You must consult your doctor before taking a rabeprazole sodium and domperidone capsules.
Losart (Losar
This document outlines the business plan for Losartan Potassium (LOSART) for 2015. It summarizes that hypertension prevalence in Bangladesh is approximately 20% according to different sources. The cardiovascular drug market is valued at 988 crores with antihypertensives comprising 636 crores. LOSART has a 29.24% share of the antihypertensive market as the second most prescribed generic. The plan identifies opportunities to increase market share by focusing on specialty physicians and improving performance in metro areas. Objectives for 2015 include achieving 10% growth, a 4.9% market share, and reaching the number 3 market position.
Dapagliflozin- a novel SGLT2 inhibitor
1) Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that works by inhibiting glucose reabsorption in the kidney and increasing glucose excretion in the urine.
2) Studies have shown that dapagliflozin reduces HbA1c and body weight when used as monotherapy or as add-on therapy to other glucose-lowering medications, including metformin, sulfonylureas, pioglitazone, and insulin. Reductions in HbA1c were sustained over 102 weeks.
3) Common side effects of dapagliflozin include increased urinary tract and genital infections, as well
Me rck’s new product development & launch strategy for
Merck was developing a new strategy to market its diabetes drug Januvia. The strategy involved using fewer sales representatives and increasing digital and online advertising. Merck found its sales force was more productive using these new methods, such as video detailing in doctors' offices. Merck also emphasized better targeting of physicians and increasing disease education for patients through tools like diabetes maps. The product manager for Januvia faced a dilemma in deciding whether to position the drug earlier or later in the progression of diabetes. Januvia saw strong initial launch with 14% of new Type 2 diabetes prescriptions. Merck competed against other diabetes drugs and was considering expanding into alternative treatment areas like insulin delivery devices, which showed a growing global market.
Prucalopride
This document discusses chronic constipation and provides information about Prulitop, a new treatment option. It summarizes that chronic constipation is a common issue, with various causes and symptoms. Current treatment options include laxatives, but these have risks if abused. Prulitop contains prucalopride, which works by agonizing 5HT4 receptors in the gut to increase fluid secretion and speed up transit time, providing an alternative to removed treatments. The document outlines the market for constipation drugs, target doctors and indications, and dosage recommendations for Prulitop.
Potassium competitive acid blocker.pptx
Pcab is new class of drug recently marketed in bangladesh.Study shows superior efficacy in comparison to conventional PPI
EXALIN Launching Presentation
The document provides market data on antihistamine drugs in Bangladesh for the first quarter of 2015. It details the total market size of 293.60 crore and lists the top selling generic drugs by value, led by cetirizine at 68.79 crore. The market share of each generic is also shown, with cetirizine and fexofenadine each holding 23% and 22% respectively. Growth rates for the market are provided, with rupatadine seeing the highest growth of 67.93%. Brand performance data for rupatadine brands in Bangladesh is outlined. Finally, the document introduces Exalin, a new 10mg rupatadine tablet from Opso Saline
Diclofenac Injection BRAND PLAN
Diclofenac Injection BRAND PLAN, Marketing activity, Pharma Brand Plan, Pharma Marketing.branding promotion, diclofenac injection brand plan, launch plan, marketing activity, pharma brand plan, pharma marketing
Oliset Olmesartan
Olmesartan medoxomil is an angiotensin II receptor antagonist which is used for the treatment of high blood pressure. An ester prodrug, it is completely and rapidly hydrolyzed to the active acid form. It is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents
Neoslim™ Final
The marketing plan proposes promoting Neoslim, a new subcutaneously administered combination anti-obesity drug, to establish it as the leading anti-obesity drug brand. The objectives are to minimize patient dropout rates, increase US market penetration and later expand to Europe. The plan details promotional tactics targeting physicians, consumers, and payers to communicate Neoslim's positioning as superior to other anti-obesity drugs. Key assumptions include Neoslim gaining greater acceptance over competitors through lower dropout rates and higher market penetration, potentially capturing the statin and Meridia markets in the US.
Vildagliptin in the management of Type 2 Diabetes mellitus
This document provides an overview of a continuing medical education (CME) program on the use of vildagliptin in managing type 2 diabetes mellitus (T2DM). The presentation covers the global burden of diabetes, pathophysiology of T2DM, limitations of current oral therapies, the incretin system, and the mechanisms and effects of DPP-4 inhibitors like vildagliptin. It discusses how vildagliptin improves pancreatic beta cell function and glucose control by prolonging the actions of incretins GLP-1 and GIP. The presentation also highlights the differences between incretin mimetics and DPP-4 inhibitors.
What's hot (20)
Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...
Review of new alerts on PROTON PUMP INHIBITORS (PPI) adverse effects 2016 UPD...
Proton pump inhibitors present and future a review
Proton pump inhibitors present and future a review
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
Rabeprazole sodium and domperidone capsules.pdf.pdf
Rabeprazole sodium and domperidone capsules.pdf.pdf
Me rck’s new product development & launch strategy for
Me rck’s new product development & launch strategy for
Vildagliptin in the management of Type 2 Diabetes mellitus
Vildagliptin in the management of Type 2 Diabetes mellitus
Similar to D-Proton.pptx
Esophagitis
Esophagitis is inflammation of the esophagus that can have various causes like acid reflux, infections, medications, radiation, and more. Common symptoms include dysphagia, heartburn, and painful swallowing. Diagnosis involves endoscopy and biopsy. Treatment depends on the underlying cause but may include lifestyle changes, antacids, H2 blockers, proton pump inhibitors, and surgery in some cases. Complications can include strictures and Barrett's esophagus.
PEPTIC ULCER
Peptic ulcer disease refers to ulcers in the stomach or duodenum caused by an imbalance of digestive fluids. Common causes include infection with H. pylori bacteria and use of NSAIDs like aspirin. Symptoms may include abdominal pain, nausea, vomiting, or blood in stool. Treatment involves eradicating H. pylori with antibiotic combinations, managing NSAID use, and prescribing proton pump inhibitors to reduce acid production and promote healing. Proton pump inhibitors are also used to treat gastroesophageal reflux disease, which occurs when stomach acid backs up into the esophagus.
proton pump inhibitors PPT
Download PPT here
https://pharmastuff.blogspot.com/2011/04/proton-pump-inhibitors-ppt-by-mrpraveen.html
Proton Pump Inhibitor (PPI)
This document discusses proton pump inhibitors (PPIs) which are a group of drugs that reduce gastric acid production. PPIs are used to treat common gastrointestinal issues like gastritis, dyspepsia, peptic ulcers, and gastroesophageal reflux disease (GERD). The causes, symptoms, and treatment approaches for each condition are described. Specifically, the document focuses on esomeprazole as a clinically used PPI and discusses its unique selling propositions and market share.
Gastrointestinal DiseasesGroup 5Leticia Bernal LeonDayd
This document discusses several gastrointestinal diseases including gastroesophageal reflux disease (GERD), gastritis, and peptic ulcer disease. It defines each condition, describes symptoms, risk factors, diagnostic tests, and treatment options. GERD is caused by acid reflux and can cause esophagitis or complications like Barrett's esophagus. Gastritis is inflammation of the stomach lining that is often caused by H. pylori or NSAIDs. Peptic ulcers develop from an imbalance between acid and mucosal protection in the esophagus, stomach, or duodenum and may be associated with H. pylori. Treatment involves eliminating triggers, reducing acid production, and treating any underlying infections.
Gastrointestinal_Disorder.pptx, GERD, Peptic Ulcer Diseases, Inflammatory Bow...
Gastrointestinal Agents covers about Peptic Ulcer, Alcoholic Liver Diseases, GERD and Inflammatory Bowel Disease
Pud final 1
A 45-year-old Saudi female presented with a 10-year history of rheumatoid arthritis and recurrent epigastric pain after eating. She was taking methotrexate and naproxen. Peptic ulcer disease is common worldwide and is usually caused by Helicobacter pylori infection or NSAID use. Diagnosis requires endoscopy or imaging. Treatment involves eradicating H. pylori with antibiotic therapy, cytoprotective agents, lifestyle changes, and sometimes surgery for complications like perforation or bleeding.
Ulcer Disease.pptx.pdf
Peptic ulcer disease refers to lesions in the stomach or duodenum caused by an imbalance between protective and corrosive factors. Common types include gastric and duodenal ulcers. H. pylori infection is present in most ulcers and its eradication can cure ulcers and reduce recurrence. Treatment involves relieving symptoms, promoting healing, and preventing complications through lifestyle modifications, medications like PPIs, H2 blockers, and antibiotics targeted against H. pylori.
acid peptic disorders
Acid peptic disorders include gastroesophageal reflux disease (GERD) and peptic ulcer disease. GERD is defined as chronic symptoms or mucosal damage caused by abnormal reflux of gastric contents into the esophagus. Peptic ulcers are defects in the gastrointestinal mucosa that extend through the muscularis mucosa. Common causes of peptic ulcers include Helicobacter pylori infection and NSAID use. Treatment involves eradicating H. pylori, discontinuing NSAIDs, and using proton pump inhibitors, H2 receptor antagonists, or prostaglandins to promote healing.
Management of peptic ulcer
Management of peptic ulcer
Ref books
1.KD Tripathi
2.HL Sharma& KK Sharma
3.Sparsh Gupta
4.S K Shriwastava
Drugs acting on GIT.pptx
This document discusses drugs acting on the gastrointestinal tract, including those used to treat peptic ulcer disease, antiemetics, and laxatives. It outlines various drug classes used for peptic ulcers like H2 receptor antagonists, proton pump inhibitors, and antibiotics for H. pylori. It also describes antiemetic drugs that work on different receptor types to treat nausea and vomiting. Finally, it covers different classes of laxatives like bulk forming, stool softeners, lubricants, osmotic, and stimulant laxatives.
Case presentation pud
Peptic ulcer disease is caused by an imbalance between aggressive gastric factors like acid and pepsin and protective mucosal defenses. H. pylori infection plays a key role in most peptic ulcers by damaging the mucosal layer. Treatment involves eradicating H. pylori with triple therapy using a PPI and two antibiotics for 2 weeks, and continuing PPI therapy for an additional 2 weeks to aid ulcer healing. Adherence to the full treatment course is important for successful eradication.
Peptic ulcer disease/ Epigastric pain
PEPTIC ULCER DISEASE- EPIGASTRIC PAIN
#surgicaleducator #epigastricabdominalpain #pepticulcerdisease #usmle #babysurgeon #surgicaltutor
• Dear Viewers,
• Greetings from “Surgical Educator”
• Today I have uploaded a video on Peptic Ulcer Disease- a didactic lecture.
• It is one of the common surgical problems you see in surgical wards.
• I have discussed the various causes for Epigastric pain, epidemiology, etiopathogenesis, clinical features, investigations, complications and treatment of Peptic Ulcer Disease.
• I have also included a mind map and a treatment algorithm for Peptic Ulcer Disease.
• I hope the video will be very useful and you will enjoy it.
• You can watch all my surgical teaching videos in the following link:
• youtube.com/c/surgicaleducator
• Thank you for watching the video.
1 anti-ulcer (gastro-group)
This document provides information on various gastro-intestinal formulations including Lantoxt tablets, Rebzm tablets, Esoje capsules, Omiject capsules, and Lenzee capsules. It describes the active ingredients, indications, dosages, and side effects of these proton pump inhibitor medications which are used to treat acid-related gastrointestinal conditions like GERD, ulcers, and Zollinger-Ellison syndrome. Packaging and pricing details are also listed for minimum order quantities between 5000 to 10000 boxes.
Ulcera42008
Peptic Ulcer Disease is defined as a circumscribed ulceration of the gastrointestinal mucosa occurring in areas exposed to acid and pepsin. The most common causes are H. pylori infection, NSAID use, and acid exposure. Symptoms include epigastric pain that may be relieved by food or antacids. Diagnosis involves stool testing, endoscopy, and the urea breath test. Treatment consists of antibiotics to eradicate H. pylori plus acid suppression medications. Lifestyle changes and preventative medications can help reduce risk of recurrence.
Pharmacology of Gastrointestinal Disorders
This power point presentation will be helpful for Pharmacy, Medical and paramedical students. it consists of" what are the common GIT disorders and their pharmacological management "
Update Treatment of Peptic Ulcer Disease dr Willy Brodus.pdf
Esomeprazole is effective for treating peptic ulcer disease and preventing rebleeding from ulcers. It works by irreversibly blocking the proton pump in the stomach, strongly inhibiting acid production. This allows platelet aggregation and clot stabilization at a gastric pH above 6. Esomeprazole maintains inhibitory effects on acid for a longer period than other PPIs, significantly reducing rebleeding rates following ulcer treatment. As a result, esomeprazole is recommended for treating bleeding ulcers and preventing their recurrence.
Peptic Ulcer _ Clinical Pharmacy
Peptic ulcer disease is characterized by sores in the stomach, duodenum, or esophagus caused by an imbalance between gastric acid and mucosal defenses. Common causes include H. pylori infection, NSAIDs, smoking, alcohol, and stress. Symptoms may include dyspepsia, abdominal pain, nausea, and weight loss. Complications can include gastrointestinal bleeding, perforation, and cancer. Diagnosis involves endoscopy and tests for H. pylori. Treatment focuses on reducing acid with PPIs or H2 blockers, eradicating H. pylori with antibiotic therapy, and lifestyle modifications.
Anti peptic ulcer drugs, by Baqir Naqvi.pptx
1. The document discusses various types of anti-peptic ulcer drugs including anti-microbial agents, H2 receptor blockers, proton pump inhibitors, and cyto-protective agents.
2. Proton pump inhibitors are the most potent gastric acid inhibitors and are the drug of choice for treating peptic ulcers and gastroesophageal reflux disease.
3. Combination therapies using anti-microbial agents along with proton pump inhibitors or H2 receptor blockers are effective treatments for H. pylori bacterial infections, which can help prevent ulcer recurrence.
Gerd1
1. Esomeprazole is a proton pump inhibitor used to treat acid-related conditions like ulcers and GERD. It works by blocking the enzyme that produces stomach acid.
2. The document discusses esomeprazole's mechanism of action, indications, dosage, side effects and compares it to other proton pump inhibitors. It also analyzes the market size and key competitors for esomeprazole.
3. A marketing strategy is proposed that involves targeting gastroenterologists and general physicians across metro and class 2 cities in India with the goal of achieving a 1.5% market share in the first year of launch.
Similar to D-Proton.pptx (20)
Gastrointestinal DiseasesGroup 5Leticia Bernal LeonDayd
Gastrointestinal DiseasesGroup 5Leticia Bernal LeonDayd
Gastrointestinal_Disorder.pptx, GERD, Peptic Ulcer Diseases, Inflammatory Bow...
Gastrointestinal_Disorder.pptx, GERD, Peptic Ulcer Diseases, Inflammatory Bow...
Update Treatment of Peptic Ulcer Disease dr Willy Brodus.pdf
Update Treatment of Peptic Ulcer Disease dr Willy Brodus.pdf
Recently uploaded
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Learn about body grief and ways to cope with it. We will also explore methods to heal from this challenging experience.
vonoprazan A novel drug for GERD presentation
Vonoprazan, a new potassium acid channel blocker used in the conditions of GERD and gastric ulcer, duodenal ulcer ....
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
The Nervous and Chemical Regulation of Respiration
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Journal Article Review on Rasamanikya
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Do you have abnormal smell after periods? It may be vaginitis. Do not worry, herbal medicine Fuyan Pill can help you get a cure.
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Histololgy of Female Reproductive System.pptx
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
It includes regulation of combination products and medical devices. FDA and industry liaisons.
Recently uploaded (20)
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
D-Proton.pptx
- 1. Presentation On Prepared by- Mostafa Kamal Group Coordinator, SBMD
- 2. Gastroesophageal reflux disease Gastroesophageal reflux disease (GERD), is defined as chronic symptoms or mucosal damage produced by the abnormal reflux of stomach acid to the esophagus. A typical symptom is heartburn.
- 3. Esophagitis Esophagitis is an inflammation of the lining of the esophagus. It may cause problems with swallowing, ulcers, and scarring of the esophagus. Reflux esophagitis Drug-induced esophagitis Infectious esophagitis Eosinophilic esophagitis Lymphocytic esophagitis
- 4. Peptic ulcer Peptic ulcer is an ulcer (defined as mucosal erosions equal to or greater than 0.5 cm) of an area of the gastrointestinal tract that is usually acidic and thus extremely painful. Gastric ulcer A peptic ulcer located at the stomach. Duodenal ulcer A peptic ulcer located at the duodenum. Esophageal ulcer A peptic ulcer located at the esophagus.
- 5. To relieve from hyper acidity & related disorders, conventional treatment options are- 1. Omeprazole 2. Esomeprazole 3. Lansoprazole 4. Rabeprazole 5. Pantoprazole
- 6. Some patients who take a PPI once daily, continue to complain of recurring heartburn specially in the late evening or overnight. Up to 40% of patients report suboptimal response to once-daily PPI therapy. The American Gastroenterological Association suggests twice- daily PPI for those who still symptomatic on once daily Long time high-dose PPI therapy may increase the risk for osteoporosis & kidney failure
- 8. Doctor TIMS introduces the latest PPI To overcome the drawback of conventional PPIs
- 9. Product orientation Brand Name D-Proton Generic Name Dexlansoprazole Strength 30 mg Dosage Form Capsule Pack size D-Proton 30 mg : 30’s Capsules Therapeutic Class Proton Pump Inhibitor Physician Sample D-Proton 30 mg :4’s Price (IP) D-Proton 30 mg: Tk. 10.00/ Cap
- 10. Brand name justification Dexlansoprazole is an ideal Proton pump inhibitor D-Proton 30
- 15. Indication & Dose D-Proton (Dexlansoprazole) dosing recommendations Indication Dose Frequency Maintenance of Healed EE and relief of heartburn 30 mg Once daily Symptomatic Non-Erosive GERD 30 mg Once daily for 4 weeks
- 17. Target Doctor Gastroenterologist Medicine Specialist Gynecologist Orthopedicians Physical Medicine General Physicians Chest Specialist ENT Specialist Diabetologist Cardiologist
- 18. Market scenario : Market Scenario: (Ref: IMS 4th Qtr, 2021) Total Market Size : 175.35 Cr Growth : 49.97% Sl. No. Brand Name Company Name MAT Valur Share % Growth % 1 DEXILEND Ziska 559,434,052 31.90 52.54 2 DEXLAN Ibn-sina 286,433,534 16.33 -1.80 3 LANSO-D Square 199,746,351 11.39 76.42 4 DELANIX Incepta 111,610,353 6.36 -13.82 5 DELANZO Novista 93,341,112 5.32 66.19 6 DEXTAC Navana 86,301,756 4.92 501.99
- 19. Marketing Guideline: Shelving & Launching date will be informed later. Rx Target : Minimum 5 Rx/day Sales Target: 15 Boxes/ Month 1.Literature 2.Sample 3.Launching celebration program 4. Gift (Air Freshener) Promotional Materials
- 24. The major tasks we have to do to survive this market Select at least 01 qualified dexlansoprazole prescribers from your territory. Ensure 5 D-Proton Rx/ Day.
- 25. T H A N K Y O U